There’s hope in the fight against colorectal cancer!

When localized to the bowel, this disease is highly treatable and often curable. Colorectal cancer is the third most common form of cancer worldwide, with an estimated 1.93 million new cases and 903,859 deaths in 2022.¹

In the United States, colorectal cancer is the second leading cause of death in men and women.² Unfortunately, 1 in 3 people in the United States who should be tested for colorectal cancer have never been screened.³

Estimated new cases and deaths from rectal and colon cancer in the United States in 2025:³

- New cases of rectal cancer: 46,950
- New cases of colon cancer: 107,320
- Deaths: 52,900 (rectal and colon cancers combined)

Screening tests can help prevent colorectal cancer³

The American Cancer Society recommends that people at average risk* of colorectal cancer start regular screening at age 45. This can be done either with a sensitive test that looks for signs of cancer in a person’s stool (a stool-based test) or a visual examination (e.g. colonoscopy).

People are considered to be at average risk* if they do not have:

- A personal history of colorectal cancer or certain types of polyps
- A family history of colorectal cancer
- A personal history of inflammatory bowel disease (ulcerative colitis or Crohn’s disease)
- A confirmed or suspected hereditary colorectal cancer syndrome, such as familial adenomatous polyposis (FAP) or Lynch syndrome (hereditary non-polyposis colon cancer or HNPCC)
- A personal history of getting radiation to the abdomen (belly) or pelvic area to treat a prior cancer

FOBT/FIT (fecal immunochemical test) Test code 6182-0

BioReference’s FOBT/FIT test offers many advantages to make the colorectal cancer screening test process more manageable for your patients, including: